This company listing is no longer active
VECT Stock Overview
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
VectivBio Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.87 |
| 52 Week High | US$16.98 |
| 52 Week Low | US$4.25 |
| Beta | 0.11 |
| 1 Month Change | 1.93% |
| 3 Month Change | 98.24% |
| 1 Year Change | 193.39% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.38% |
Recent News & Updates
Shareholder Returns
| VECT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.1% | -4.2% | -3.7% |
| 1Y | 193.4% | -2.0% | 20.5% |
Return vs Industry: VECT exceeded the US Biotechs industry which returned 6% over the past year.
Return vs Market: VECT exceeded the US Market which returned 14% over the past year.
Price Volatility
| VECT volatility | |
|---|---|
| VECT Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VECT's share price has been volatile over the past 3 months.
Volatility Over Time: VECT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Luca Santarelli | vectivbio.com |
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD).
VectivBio Holding AG Fundamentals Summary
| VECT fundamental statistics | |
|---|---|
| Market cap | US$1.06b |
| Earnings (TTM) | -US$93.73m |
| Revenue (TTM) | US$27.34m |
38.8x
P/S Ratio-11.3x
P/E RatioIs VECT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VECT income statement (TTM) | |
|---|---|
| Revenue | US$27.34m |
| Cost of Revenue | US$0 |
| Gross Profit | US$27.34m |
| Other Expenses | US$121.08m |
| Earnings | -US$93.73m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | 100.00% |
| Net Profit Margin | -342.84% |
| Debt/Equity Ratio | 4.8% |
How did VECT perform over the long term?
See historical performance and comparison